Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (11,644,966)	$ (37,866,414)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	763,020	1,189,988
Depreciation	30,758	54,866
Amortization of debt discount	474,570
Inducement expense	2,567,044
Change in fair value of derivative instrument-warrants	(4,506,633)
Change in fair value of contingent consideration	(2,020,000)	(180,000)
Changes in operating assets and liabilities:
Accounts payable and accrued expenses	(4,297,192)	1,430,993
Right of use asset	94,577	50,585
Operating lease liability	(91,068)	(54,578)
Prepaid expenses and other assets	1,566,461	3,487,456
Net cash used in operating activities	(17,063,429)	(31,887,104)
Cash flows from investing activities:
Purchase of property and equipment		(13,956)
Investment in related party receivable	(600,000)
Net cash used in investing activities	(600,000)	(13,956)
Cash flows from financing activities:
Proceeds from exercise of the warrants, net	1,849,707
Proceeds from equity and debt issuance under SPA, net of discount	2,500,000
Net cash provided by financing activities	4,349,707
Effect of exchange rates on cash	24,948	(3,948)
Net decrease in cash	(13,288,774)	(31,905,008)
Cash at beginning of period	14,785,880	51,189,088
Cash at end of period	1,497,106	19,284,080
Supplementary disclosure of non-cash financing activities:
Conversion of Series C convertible preferred stock		1,000
Inducement expense for issuance of Series B-1 and B-2 warrants	2,821,399
Stock-based liability awards reversed to additional paid-in capital		2,983,006
Operating lease asset additions		$ 242,507